Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
Several companies have announced new executives and board members appointments as they prepare for growth in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback